Meta-analysis finds no benefit of IV thrombolysis for minor ischemic strokeClot-busting drugs did not improve function but raised bleeding risk for minor strokes

Frontiers in Medicine Published April 29, 2026 DOI ↗ Editorial oversight: Dr. Ji-eun Park, MD · Brain, Mind & Pain

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider that IVT for minor ischemic stroke shows no clear functional benefit and increases sICH risk.

This systematic review and meta-analysis of randomized controlled trials evaluated the efficacy and safety of intravenous thrombolysis (IVT) compared with standard medical management (SMM) in patients with minor ischemic stroke, defined as National Institutes of Health Stroke Scale (NIHSS) score ≤5. The analysis included 4,361 patients from multiple trials, with follow-up at 90 days.

The primary outcome of excellent functional outcome (modified Rankin Scale score 0–1) at 90 days showed no significant difference between IVT and SMM (OR 0.85; 95% CI 0.72–1.00). Similarly, the secondary outcome of functional independence (mRS 0–2) also showed no significant difference (OR 0.85; 95% CI 0.63–1.13).

Regarding safety, IVT was associated with a significantly higher risk of symptomatic intracranial hemorrhage (sICH) compared with SMM (OR 4.70; 95% CI 1.76–12.52). There was no significant difference in 90-day all-cause mortality (OR 1.62; 95% CI 0.69–3.79).

The authors did not report specific limitations, but the confidence intervals for the primary outcome approach significance, and the increased sICH risk is notable. The practice relevance is that routine use of IVT in minor stroke should be approached with caution, as the benefit is uncertain and the risk of harm is elevated.

People with minor strokes often face a hard choice: take strong medicine to clear a clot or rely on standard care. A massive review looked at 4,361 patients with minor ischemic stroke to see if intravenous thrombolysis, or IVT, helped them recover better. This treatment uses a drug to dissolve the blockage causing the stroke. The researchers compared it to standard medical management, which involves treating the stroke without clot-busting drugs. The goal was to see if the drug helped patients regain full function within 90 days. The results were clear and sobering. The drug did not make patients more likely to have an excellent recovery. In fact, the risk of a dangerous brain bleed was much higher for those who took the clot-busting medicine. This bleeding is a serious complication that can worsen the injury. The chance of dying within 90 days did not change between the two groups. This study suggests that doctors should be very careful before using these powerful drugs for minor strokes. The potential harm of bleeding outweighs the lack of proven benefit for this specific group of patients.

What this means for you:

Clot-busting drugs raised bleeding risk without improving recovery for minor strokes.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedApr 2026

View Original Abstract ↓

BackgroundThe efficacy and safety of intravenous thrombolysis (IVT) compared to standard medical management (SMM) remain unclear in patients with minor ischemic stroke (National Institutes of Health Stroke Scale [NIHSS] ≤ 5). This meta-analysis of randomized controlled trials (RCTs) aimed to synthesize evidence from a direct comparison of these treatments.MethodsWe systematically searched PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov from inception to June 30th, 2025. The primary efficacy outcome was an excellent functional outcome (modified Rankin Scale [mRS] score 0–1) at 90 days. The secondary efficacy outcome was functional independence (mRS score 0–2) at 90 days. Key safety outcomes included symptomatic intracranial hemorrhage (sICH) and 90-day all-cause mortality. Data were analyzed using a random-effects model. This study was registered with PROSPERO (CRD420251089799).ResultsFive RCTs involving 4,361 patients were included. The meta-analysis revealed no significant difference between IVT and SMM in efficacy, both for the primary efficacy outcome (90-day mRS 0–1: OR 0.85, 95% CI 0.72–1.00) or the secondary efficacy outcome (90-day mRS 0–2: OR 0.85, 95% CI 0.63–1.13). Regarding safety, the risk of sICH was significantly higher in the IVT group (OR 4.70, 95% CI 1.76–12.52), whereas no significant difference was found in 90-day all-cause mortality (OR 1.62, 95% CI 0.69–3.79).ConclusionIn patients with minor ischemic stroke, IVT offers no superior benefit in functional outcomes over SMM but significantly increases sICH risk. Therefore, routine use of IVT should be approached with caution. Future research should identify specific subgroups who might benefit.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251089799.

Meta-analysis finds no benefit of IV thrombolysis for minor ischemic strokeClot-busting drugs did not improve function but raised bleeding risk for minor strokes

Study Details

Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke

Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window

Clinical research that matters. Delivered to your inbox.

Meta-analysis finds no benefit of IV thrombolysis for minor ischemic strokeClot-busting drugs did not improve function but raised bleeding risk for minor strokes

More on Stroke

Study Details

Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke

Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window

Clinical research that matters. Delivered to your inbox.

Related in Neurology

From Other Specialties